Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.3 (
phospholipase C
)
18,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Until recently, the signaling events elicited in vascular smooth muscle cells by angiotensin II (
Ang II
) were considered to be rapid, short-lived, and divided into separate linear pathways, where intracellular targets of the
phospholipase C
-diacylglycerol-Ca(2+) axis were distinct from those of the tyrosine kinase- and mitogen-activated protein kinase- dependent pathways. However, these major intracellular signaling cascades do not function independently and are actively engaged in cross-talk. Downstream signals from the
Ang II
-bound receptors converge to elicit complex and multiple responses. The exact adapter proteins or "go-between" molecules that link the multiple intracellular pathways await clarification.
Ang II
induces a multitude of actions in various tissues, and the signaling events following occupancy and activation of angiotensin receptors are tightly controlled and extremely complex. Alterations of these highly regulated signaling pathways in vascular smooth cells may be pivotal in structural and functional abnormalities that underlie vascular pathological processes in cardiovascular diseases such as hypertension, atherosclerosis, and post-interventional restenosis.
...
PMID:Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. 1112 12
The cloning of the avian
Ang II
receptor shows that it is molecularly close to the AT(1)-type mammalian receptor. However, pharmacological characterization in transfected cells shows that, even though the avian receptor is coupled to the
phospholipase C
, as is the AT(1), its profile of specificity towards antagonists appears different from that of the two angiotensin II mammalian receptor types. The fowl
Ang II
receptor mRNA is expressed in classical adult target organs for
Ang II
and, interestingly, also in endothelial cells, but not in vascular smooth muscle cells. In the endothelial cells, it may mediate the peculiar vasorelaxation effect of
Ang II
already reported in the chicken. The recent description of the expression pattern in the chick embryo shows that the avian
Ang II
receptor is expressed in many different mesenchymal tissues, a feature which is the signature of the AT(2) mammalian receptor. Altogether, these data imply that the avian
Ang II
receptor is an atypical receptor that cannot be readily classified as either of the two mammalian
Ang II
receptor types and, therefore, reinforce the evidence for another
Ang II
receptor in the avian class.
...
PMID:Angiotensin receptor(s) in fowl. 1113 40
Angiotensin (
Ang II
) activates neuronal AT(1) receptors located in the hypothalamus and the brainstem and stimulates noradrenergic neurons that are involved in the control of blood pressure and fluid intake. In this study we used complementary DNA microarrays for high throughput gene expression profiling to reveal unique genes that are linked to the neuromodulatory actions of
Ang II
in neuronal cultures from newborn rat hypothalamus and brainstem. Of several genes that were regulated, we focused on calmodulin and synapsin I.
Ang II
(100 nM; 1-24 h) elicited respective increases and decreases in the levels of calmodulin and synapsin I messenger RNAs, effects mediated by AT(1) receptors. This was associated with similar changes in calmodulin and synapsin protein expression. The actions of
Ang II
on calmodulin expression involve an intracellular pathway that includes activation of
phospholipase C
, increased intracellular calcium, and stimulation of protein kinase C. Taken together with studies that link calmodulin and synapsin I to axonal transport and exocytotic processes, the data suggest that
Ang II
regulates these two proteins via a Ca(2+)-dependent pathway, and that this may contribute to longer term or slower neuromodulatory actions of this peptide.
...
PMID:Gene expression profiling of rat brain neurons reveals angiotensin II-induced regulation of calmodulin and synapsin I: possible role in neuromodulation. 1118 13
-The anti-inflammatory effects of salicylate are well known, but the intracellular mechanisms underlying those effects remain to be clarified and are not explained solely by an influence on cyclooxygenase activity. In the present study, we have used cardiac fibroblasts stimulated by either angiotensin II (
Ang II
) or platelet-derived growth factor (PDGF) to demonstrate an inhibitory effect of salicylate on the phosphorylation of the nonreceptor tyrosine kinases, proline-rich tyrosine kinase 2 (PYK2) and c-Src, by immunoprecipitation and immunoblotting methods. This inhibition was dose dependent, with a clear effect observed at concentrations between 5 and 20 mmol/L salicylate. Intracellular Ca(2+) chelation and protein kinase C (PKC) inhibition reduced
Ang II
and PDGF-induced PYK2 and c-Src phosphorylation. Salicylate significantly inhibited the phosphorylation of both of the tyrosine kinases activated by either ionophore A23187 or thapsigargin treatment, which led to an elevation of cytosolic Ca(2+). Activation of PKC by phorbol ester phosphorylated both PYK2 and Src, and this effect also was attenuated by salicylate. In contrast, salicylate had no effect on either the transactivation of the epidermal growth factor receptor by
Ang II
or the phosphorylation of
phospholipase C
-gamma by PDGF. These studies indicate a novel site of action for salicylate on PYK2 and c-Src phosphorylation and suggest that this inhibitory effect on these important signaling intermediates may be through a Ca(2+)- and PKC-dependent mechanism.
...
PMID:Salicylate Inhibits Phosphorylation of the Nonreceptor Tyrosine Kinases, Proline-Rich Tyrosine Kinase 2 and c-Src. 1120 70
Angiotensin (Ang)-(1-7) is a biologically active peptide of the renin-angiotensin system that has both vasodilatory and antiproliferative activities that are opposite the constrictive and proliferative effects of angiotensin II (
Ang II
). We studied the actions of Ang-(1-7) on the
Ang II
type 1 (AT(1)) receptor in cultured rat aortic vascular smooth muscle cells to determine whether the effects of Ang-(1-7) are due to its regulation of the AT(1) receptor. Ang-(1-7) competed poorly for [(125)I]
Ang II
binding to the AT(1) receptor on vascular smooth muscle cells, with an IC(50) of 2.0 micromol/L compared with 1.9 nmol/L for
Ang II
. The pretreatment of vascular smooth muscle cells with Ang-(1-7) followed by treatment with acidic glycine to remove surface-bound peptide resulted in a significant decrease in [(125)I]
Ang II
binding; however, reduced
Ang II
binding was observed only at micromolar concentrations of Ang-(1-7). Scatchard analysis of vascular smooth muscle cells pretreated with 1 micromol/L Ang-(1-7) showed that the reduction in
Ang II
binding resulted from a loss of the total number of binding sites [B(max) 437.7+/-261.5 fmol/mg protein in Ang-(1-7)-pretreated cells compared with 607.5+/-301.2 fmol/mg protein in untreated cells, n=5, P<0.05] with no significant effect on the affinity of
Ang II
for the AT(1) receptor. Pretreatment with the AT(1) receptor antagonist L-158,809 blocked the reduction in [(125)I]
Ang II
binding by Ang-(1-7) or
Ang II
. Pretreatment of vascular smooth muscle cells with increasing concentrations of Ang-(1-7) reduced
Ang II
-stimulated
phospholipase C
activity; however, the decrease was significant (81.2+/-6.4%, P<0.01, n=5) only at 1 micromol/L Ang-(1-7). These results demonstrate that pharmacological concentrations of Ang-(1-7) in the micromolar range cause a modest downregulation of the AT(1) receptor on vascular cells and a reduction in
Ang II
-stimulated
phospholipase C
activity. Because the antiproliferative and vasodilatory effects of Ang-(1-7) are observed at nanomolar concentrations of the heptapeptide, these responses to Ang-(1-7) cannot be explained by competition of Ang-(1-7) at the AT(1) receptor or Ang-(1-7)-mediated downregulation of the vascular AT(1) receptor.
...
PMID:Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. 1130 16
In spontaneously hypertensive rats (SHR), hypertension is mediated in part by an enhanced renovascular response to angiotensin (Ang) II. Pertussis toxin normalizes renovascular responses to
Ang II
and lowers blood pressure in SHR, suggesting a role for altered G(i) signaling in the enhanced renovascular response to
Ang II
in SHR. To further investigate this hypothesis, we measured reductions in renal blood flow and increases in renovascular resistance in response to intrarenal infusions of
Ang II
in the presence and absence of coactivation of alpha(2)-adrenoceptors (ie, receptors selectively coupled to G(i)) with UK 14,304 in adrenalectomized, renal-denervated, captopril-pretreated SHR and normotensive Wistar-Kyoto rats. In SHR, but not Wistar-Kyoto rats, UK 14,304 markedly enhanced renovascular responses to
Ang II
and vasopressin. However, UK 14,304 did not enhance renovascular responses to methoxamine (alpha(1)-adrenoceptor agonist) in either strain. In uninephrectomized, normotensive Sprague-Dawley animals and in Sprague-Dawley rats with nongenetic hypertension induced by uninephrectomy, chronic administration of deoxycorticosterone acetate, and 1% saline as drinking water, UK 14,304 had little or no effect on renovascular responses to
Ang II
. In SHR, intrarenal infusions of U73122, a
phospholipase C
/D inhibitor, blocked the enhancement of renovascular responses to
Ang II
by UK 14,304. We conclude that activation of alpha(2)-adrenoceptors selectively enhances renovascular responses to
Ang II
and vasopressin in vivo in animals with genetic hypertensive but not in normotensive animals or animals with acquired hypertension. These results suggest that in SHR, there is a genetically mediated enhanced cross talk between the G(i) signal transduction pathway and signal transduction pathways activated by
Ang II
and vasopressin, but not methoxamine, and involving
phospholipase C
and/or D.
...
PMID:Enhanced interaction between renovascular alpha(2)-adrenoceptors and angiotensin II receptors in genetic hypertension. 1156 4
We investigated the ganglionic effects of angiotensin II (
Ang II
) and the signal transduction involved in the cardiac sympathetic ganglia by the direct administration of agents to the ganglia through the right subclavian artery and monitoring the heart rate as an indicator of the ganglionic function in pithed dogs.
Ang II
given i.a. caused increases in the heart rate, which was inhibited by the treatment with the AT1-receptor antagonist forasartan, but not by the AT2-receptor antagonist PD-123319. The stimulation by
Ang II
, but not by acetylcholine, was inhibited after treatment with an inhibitor of
phospholipase C
, U-73122; a cell-permeant modulator of the Ins(1,4,5)P3 receptors, 2-aminoethoxydiphenyl borate; an intracellular calcium and calcium-associated protein kinase inhibitor, HA-1077; calmodulin (CaM) inhibitor, W-7; Ca2+/CaM-dependent protein kinase II inhibitor, KN-93; a selective protein kinase C inhibitor, calphostin C; and Na+H+ exchange inhibitor, dimethylamiloride. These results suggest that
Ang II
stimulates the ganglionic transmission at postsynaptic sites via the activation of AT1 receptor coupled to either activation of
phospholipase C
, phosphoinositide hydrolysis and subsequent increase in intracellular Ca2+ and activation of protein kinase C and Ca2+/CaM kinase II, although this ganglionic stimulation seems to involve, at least in part, the protein kinases-dependent increase of amiloride-sensitive Na+ inflow.
...
PMID:Possible involvement of calcium-calmodulin pathways in the positive chronotropic response to angiotensin II on the canine cardiac sympathetic ganglia. 1156 11
Although the presence of intracellular angiotensin II (
Ang II
) and of
Ang II
-binding sites has been reported, their roles in cell function have not been fully clarified. The purpose of the present study was to test the hypothesis that intracellular
Ang II
modifies voltage-operated Ca(2+) channels in vascular smooth muscle. Ca(2+) channel currents were recorded in guinea pig mesenteric arterial myocytes with the whole-cell patch-clamp method. Intracellular dialysis of
Ang II
increased the amplitudes of Ca(2+) channel current (133 +/- 9% of the control with 10 nmol/L
Ang II
, n=16). Concomitant dialysis of the
Ang II
type 1 receptor antagonist, CV-11974 (1 micromol/L, n=11), but not the bath application of this drug, suppressed this
Ang II
action. In contrast, the dialysis of the
Ang II
type 2 receptor antagonist, PD123319 (1 micromol/L, n=5), failed to affect the
Ang II
action. Dialysis of either a
phospholipase C
inhibitor (U-73122, 10 micromol/L, n=5) or protein kinase C inhibitors (calphostin C, 100 nmol/L, n=5; protein kinase C inhibitor peptide-[19-36], 1 micromol/L, n=5) suppressed the
Ang II
action. Dialysis of KT5720 (100 nmol/L, n=5), an inhibitor of cAMP-dependent protein kinase, did not affect the
Ang II
action. Intracellular dialysis of angiotensin I (10 nmol/L) enhanced Ca(2+) channel currents (13 3 +/- 8%, n=6), which were sensitive to intracellular enalaprilat (1 micromol/L, n=5) or CV-11974 (n=5). These results suggest that intracellular
Ang II
has a stimulating action on voltage-operated Ca(2+) channels in vascular smooth muscle, possibly through intracellular binding sites similar to the
Ang II
type 1 receptor, which are associated with
phospholipase C
and protein kinase C.
...
PMID:Intracellular angiotensin II stimulates voltage-operated Ca(2+) channels in arterial myocytes. 1188 93
Angiotensin II (
Ang II
) plays an important role in the central control of blood pressure and baroreflexes. These effects are initiated by stimulation of
Ang II
type 1 (AT(1)) receptors on neurons within the hypothalamus and brain stem, and involve increasing the activity of noradrenergic, substance P, and glutamatergic pathways. The goal of this study is to investigate the intracellular signaling molecules, which are involved in mediating the
Ang II
-induced increases in neuronal activity. Using neurons in primary culture from newborn rat hypothalamus and brain stem, we have previously determined that
Ang II
elicits an AT(1) receptor-mediated inhibition of delayed rectifier K(+) current, a stimulation of Ca(2+) current, and a consequent increase in firing rate. In the present study we have demonstrated that this chronotropic action of
Ang II
in neuronal cultures involves activation of Ca(2+)-dependent signaling molecules. The
Ang II
-induced increase in firing rate was abolished by inhibition of
phospholipase C
with U73122 (10 micromol/L), and was attenuated by the protein kinase C inhibitor calphostin C (10 micromol/L) or by the calcium/calmodulin-dependent kinase II (CaMKII) inhibitor KN-93 (10 micromol/L). A combination of calphostin C and KN-93 completely inhibited this
Ang II
action. These results indicate that the AT(1) receptor-mediated increase in neuronal firing rate involves activation of both PKC and CaMKII, and suggest that these enzymes are potential targets for manipulating the central actions of
Ang II
.
...
PMID:Chronotropic action of angiotensin II in neurons via protein kinase C and CaMKII. 1188 8
Intracellular signal transduction pathways involved in ATP release evoked by angiotensin II (
Ang II
) were investigated in cultured guinea pig Taenia coli smooth muscle cells.
Ang II
(0.3-1 microM) elicited substantial release of ATP from the cells, but not from a human fibroblast cell line. However,
Ang II
even at 10 microM failed to cause a leakage of lactate dehydrogenase (LDH) from the smooth muscle cells. The release of ATP by
Ang II
was suppressed by 10 microM SC52458, an AT1 receptor antagonist, not by 10 microM PD123319, an AT2 receptor antagonist. The evoked release of ATP was almost completely inhibited in the presence of 10 microM U73122, a
phospholipase C
inhibitor, and 0.5 microM thapsigargin, a Ca2+-ATPase inhibitor. Furthermore, the release was hampered by 50 microM BAPTA/AM, an intracellular Ca2+ chelator, but not by 0.1 microM nifedipine, a voltage gated Ca2+ channel inhibitor. The basal release of ATP was increased by BAPTA/AM, but was reduced by U-73122.
Ang II
enhanced instantaneously inositol(1,4,5)trisphosphate (Ins(1,4,5)P3) accumulation in the cells. The enhancing effect was perfectly antagonized by SC52458. These findings suggest that intracellular Ca2+ signals activated via stimulation of Ins(1,4,5)P3 receptor are involved in the release of ATP evoked by
Ang II
.
...
PMID:Inositol(1,4,5)trisphosphate signal triggers a receptor-mediated ATP release. 1205 23
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>